523 related articles for article (PubMed ID: 35069590)
1. T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
Campe J; Ullrich E
Front Immunol; 2021; 12():806529. PubMed ID: 35069590
[TBL] [Abstract][Full Text] [Related]
2. Targeting Inflammatory T Helper Cells
Buchele V; Abendroth B; Büttner-Herold M; Vogler T; Rothamer J; Ghimire S; Ullrich E; Holler E; Neurath MF; Hildner K
Front Immunol; 2018; 9():1138. PubMed ID: 29910804
[TBL] [Abstract][Full Text] [Related]
3. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
4. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
5. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
Front Immunol; 2021; 12():757836. PubMed ID: 34712243
[TBL] [Abstract][Full Text] [Related]
6. Identification of Casz1 as a Regulatory Protein Controlling T Helper Cell Differentiation, Inflammation, and Immunity.
Bhaskaran N; Liu Z; Saravanamuthu SS; Yan C; Hu Y; Dong L; Zelenka P; Zheng L; Bletsos V; Harris R; Harrington B; Weinberg A; Thiele CJ; Ye F; Pandiyan P
Front Immunol; 2018; 9():184. PubMed ID: 29467767
[TBL] [Abstract][Full Text] [Related]
7. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
8. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.
Wu Y; Bastian D; Schutt S; Nguyen H; Fu J; Heinrichs J; Xia C; Yu XZ
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1195-204. PubMed ID: 25846718
[TBL] [Abstract][Full Text] [Related]
9. Development, regulation and functional capacities of Th17 cells.
Hirota K; Martin B; Veldhoen M
Semin Immunopathol; 2010 Mar; 32(1):3-16. PubMed ID: 20107806
[TBL] [Abstract][Full Text] [Related]
10. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.
Yi T; Zhao D; Lin CL; Zhang C; Chen Y; Todorov I; LeBon T; Kandeel F; Forman S; Zeng D
Blood; 2008 Sep; 112(5):2101-10. PubMed ID: 18596226
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation.
Sundrud MS; Grill SM; Ni D; Nagata K; Alkan SS; Subramaniam A; Unutmaz D
J Immunol; 2003 Oct; 171(7):3542-9. PubMed ID: 14500650
[TBL] [Abstract][Full Text] [Related]
13. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity and plasticity of T helper cells.
Zhu J; Paul WE
Cell Res; 2010 Jan; 20(1):4-12. PubMed ID: 20010916
[TBL] [Abstract][Full Text] [Related]
15. CD4 CTL: living up to the challenge.
Cheroutre H; Husain MM
Semin Immunol; 2013 Nov; 25(4):273-81. PubMed ID: 24246226
[TBL] [Abstract][Full Text] [Related]
16. A critical role for donor-derived IL-22 in cutaneous chronic GVHD.
Gartlan KH; Bommiasamy H; Paz K; Wilkinson AN; Owen M; Reichenbach DK; Banovic T; Wehner K; Buchanan F; Varelias A; Kuns RD; Chang K; Fedoriw Y; Shea T; Coghill J; Zaiken M; Plank MW; Foster PS; Clouston AD; Blazar BR; Serody JS; Hill GR
Am J Transplant; 2018 Apr; 18(4):810-820. PubMed ID: 28941323
[TBL] [Abstract][Full Text] [Related]
17. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease.
Iclozan C; Yu Y; Liu C; Liang Y; Yi T; Anasetti C; Yu XZ
Biol Blood Marrow Transplant; 2010 Feb; 16(2):170-8. PubMed ID: 19804837
[TBL] [Abstract][Full Text] [Related]
18. PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 activation.
Lee SH; Moon SJ; Park MJ; Kim EK; Moon YM; Cho ML
Immunol Lett; 2014 Jul; 160(1):79-88. PubMed ID: 24718277
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations.
Zhao C; Zhang Y; Zheng H
Front Immunol; 2021; 12():717540. PubMed ID: 34305954
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.
Yi T; Chen Y; Wang L; Du G; Huang D; Zhao D; Johnston H; Young J; Todorov I; Umetsu DT; Chen L; Iwakura Y; Kandeel F; Forman S; Zeng D
Blood; 2009 Oct; 114(14):3101-12. PubMed ID: 19602708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
